PT  - JOURNAL ARTICLE
AU  - Patel, Hamel
AU  - Ashton, Nicholas J
AU  - Dobson, Richard J.B
AU  - Andersson, Lars-Magnus
AU  - Yilmaz, Aylin
AU  - Blennow, Kaj
AU  - Gisslen, Magnus
AU  - Zetterberg, Henrik
TI  - Proteomic blood profiling in mild, severe and critical COVID-19 patients
AID  - 10.1101/2020.06.22.20137216
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.06.22.20137216
4099  - http://medrxiv.org/content/early/2020/06/23/2020.06.22.20137216.short
4100  - http://medrxiv.org/content/early/2020/06/23/2020.06.22.20137216.full
AB  - The recent SARS-CoV-2 pandemic manifests itself as a mild respiratory tract infection in the majority of individuals leading to COVID-19 disease. However, in some infected individuals, this can progress to severe pneumonia and acute respiratory distress syndrome (ARDS), leading to multi-organ failure and death. The purpose of this study is to explore the proteomic differences between mild, severe and critical COVID-19 positive patients. Blood protein profiling was performed on 59 COVID-19 mild (n=26), severe (n=9) or critical (n=24) cases and 28 controls using the OLINK inflammation, autoimmune, cardiovascular and neurology panels. Differential expression analysis was performed within and between disease groups to generate nine different analyses. From the 368 proteins measured per individual, more than 75% were observed to be significantly perturbed in COVID-19 cases. Six proteins (IL6, CKAP4, Gal-9, IL-1ra, LILRB4 and PD-L1) were identified to be associated with disease severity. The results have been made readily available through an interactive web-based application for instant data exploration and visualization, and can be accessed at https://phidatalab-shiny.rosalind.kcl.ac.uk/COVID19/. Our results demonstrate that dynamic changes in blood proteins that associate with disease severity can potentially be used as early biomarkers to monitor disease severity in COVID-19 and serve as potential therapeutic targets.Competing Interest StatementKB has served as a consultant, at advisory boards, or at data monitoring committees for Abcam, Axon, Biogen, Julius Clinical, Lilly, MagQu, Novartis, Roche Diagnostics, and Siemens Healthineers, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside submitted work). HZ has served at scientific advisory boards for Denali, Roche Diagnostics, Wave, Samumed, Siemens Healthineers, Pinteon Therapeutics and CogRx, has given lectures in symposia sponsored by Fujirebio, Alzecure and Biogen, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside submitted work).Funding StatementThis study presents independent research supported by the NIHR BioResource Centre Maudsley at South London and Maudsley NHS Foundation Trust (SLaM) & Institute of Psychiatry, Psychology and Neuroscience (IoPPN), Kings College London. The views expressed are those of the author(s) and not necessarily those of the NHS, NIHR, Department of Health or Kings College London. The authors acknowledge use of the research computing facility at Kings College London, Rosalind (https://rosalind.kcl.ac.uk), which is delivered in partnership with the National Institute for Health Research (NIHR) Biomedical Research Centres at South London & Maudsley and Guys & St. Thomas NHS Foundation Trusts, and part-funded by capital equipment grants from the Maudsley Charity (award 980) and Guys & St. Thomas Charity (TR130505). The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR, Kings College London, or the Department of Health and Social Care. NJA is supported by the Wallenberg Centre for Molecular and Translational Medicine, the Swedish Alzheimer Foundation (Alzheimerfonden), the Swedish Dementia Foundation (Demensforbundet), Hjarnfonden, Sweden and the Anna Lisa and Brother Bjornssons Foundation. RJBD is supported by 1. Health Data Research UK, which is funded by the UK Medical Research Council, Engineering and Physical Sciences Research Council, Economic and Social Research Council, Department of Health and Social Care (England), Chief Scientist Office of the Scottish Government Health and Social Care Directorates, Health and Social Care Research and Development Division (Welsh Government), Public Health Agency (Northern Ireland), British Heart Foundation and Wellcome Trust. 2. The National Institute for Health Research University College London Hospitals Biomedical Research Centre. KB is supported by the Swedish Research Council (#2017-00915), the Alzheimer Drug Discovery Foundation (ADDF), USA (#RDAPB-201809-2016615), the Swedish Alzheimer Foundation (#AF-742881), Hjarnfonden, Sweden (#FO2017-0243), the Swedish state under the agreement between the Swedish government and the County Councils, the ALF-agreement (#ALFGBG-715986), and European Union Joint Program for Neurodegenerative Disorders (JPND2019-466-236). MG is supported by The Swedish State Support for Clinical Research (ALFGBG-717531) and by SciLifeLab/KAW national COVID-19 research program project grant (V-2020-0250). HZ is a Wallenberg Scholar supported by grants from the Swedish Research Council (#2018-02532), the European Research Council (#681712), Swedish State Support for Clinical Research (#ALFGBG-720931), the Alzheimer Drug Discovery Foundation (ADDF), USA (#201809-2016862), and the UK Dementia Research Institute at UCL.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study has been approved by the Swedish Ethical Review Authority (2020-01771). All participants provided written informed consent, in those with severe COVID-19, this was obtained before they were placed on mechanical ventilation and were deemed fully capable of understanding the nature of the study and their part in.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe proteomic data is available in the BioStudies database (http://www.ebi.ac.uk/biostudies) under accession number S-BSST416. Additionally, an R shiny application was written in R using the “shiny” framework (version 1.4.0.2) to allow the quick and efficient visualization of the expression of specific proteins across the control, mild, severe and severe symptom groups. The application is hosted on the research computing facility at King’s College London (Rosalind), and allows researchers to quickly visualize and investigate the results across all nine DE analyses performed in this study. The application can be accessed at https://phidatalab-shiny.rosalind.kcl.ac.uk/COVID19/. All data analysis scripts used in this study have been deposited in zenodo under the DOI: 10.5281/zenodo.3895886